Human duodenal proteome modulations by glutamine and antioxidants

Proteomics - Clinical Applications

Volumn 4, Issue 3, 2010, Pages 325-336

  Thébault, Sandrine ^a   Deniel, Nicolas ^a   Galland, Alexandra ^b   Lecleire, Stéphane ^a   Charlionet, Roland ^c   Coëffier, Moïse ^a   Tron, François ^c   Vaudry, David ^b   Déchelotte, Pierre ^a  

^a Faculté de Médecine Pharmacie   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c faculté mixte de médecine et de pharmacie de Rouen   (France)

Author keywords

Antioxidant; Duodenum; Glutamine; Nutrition

Indexed keywords

ANTIOXIDANT; FATTY ACID BINDING PROTEIN; GLUTAMINE; MANGANESE SUPEROXIDE DISMUTASE; PROTEOME; RETINAL DEHYDROGENASE; RIBOSOME PROTEIN; TRACE ELEMENT;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN REGULATION; DUODENUM; DUODENUM BIOPSY; ENDOSCOPIC BIOPSY; ENTERITIS; HUMAN; HUMAN EXPERIMENT; INTESTINE FUNCTION; METABOLISM; NORMAL HUMAN; NUTRITION; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; FEMALE; GENE EXPRESSION REGULATION; GLUTAMINE; HUMANS; MALE; MICRONUTRIENTS; PILOT PROJECTS; PROTEOME; YOUNG ADULT;

ANIMALIA;

EID: 77951733097     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200800175     Document Type: Article

References (66)

1. Wang, J., Li, D., Dangott, L.J., Wu, G., Proteomics and its role in nutrition research. J. Nutr. 2006, 136, 1759-1762.
2. Kussmann, M., Blum, S., OMICS-derived targets for inflammatory gut disorders: opportunities for the development of nutrition related biomarkers. Endocr. Metab. Immune Disord. Drug Targets 2007, 7, 271-287.
3. Lenaerts, K., Bouwman, F.G., Lamers, W.H., Renes, J., Mariman, E.C., Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics 2007, 8, 91.
4. Thebault, S., Deniel, N., Marion, R., Charlionet, R. et al., Proteomic analysis of glutamine-treated human intestinal epithelial HCT-8 cells under basal and inflammatory conditions. Proteomics 2006, 6, 3926-3937.
5. Deniel, N., Marion-Letellier, R., Charlionet, R., Tron, F. et al., Glutamine regulates the human epithelial intestinal HCT-8 cell proteome under apoptotic conditions. Mol. Cell Proteomics 2007, 6, 1671-1679.
6. Lenaerts, K., Sokolovic, M., Bouwman, F.G., Lamers, W.H. et al., Starvation induces phase-specific changes in the proteome of mouse small intestine. J. Proteome Res. 2006, 5, 2113-2122.
7. Iiizumi, G., Sadoya, Y., Hino, S., Shibuya, N., Kawabata, H., Proteomic characterization of the site-dependent functional difference in the rat small intestine. Biochim. Biophys. Acta 2007, 1774, 1289-1298.
8. Shkoda, A., Werner, T., Daniel, H., Gunckel, M. et al., Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J. Proteome Res. 2007, 6, 1114-1125.
9. Bi, X., Lin, Q., Foo, T.W., Joshi, S. et al., Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol. Cell Proteomics 2006, 5, 1119-1130.
10. Stulik, J., Hernychova, L., Porkertova, S., Knizek, J. et al., Proteome study of colorectal carcinogenesis. Electrophoresis 2001, 22, 3019-3025.
11. Tomonaga, T., Matsushita, K., Yamaguchi, S., Oh-Ishi, M. et al., Identification of altered protein expression and posttranslational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res. 2004, 10, 2007-2014.
12. Polley, A.C., Mulholland, F., Pin, C., Williams, E.A. et al., Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res. 2006, 66, 6553-6562.
13. Song, K., Hanash, S., Unraveling the complex proteome for biomarker discovery in gastrointestinal and liver diseases. Gastroenterology 2006, 131, 1375-1378.
14. Curi, R., Newsholme, P., Procopio, J., Lagranha, C. et al. Glutamine, gene expression, and cell function. Front. Biosci. 2007, 12, 344-357.
15. Bongers, T., Griffiths, R.D., McArdle, A., Exogenous glutamine: the clinical evidence. Crit. Care Med. 2007, 35, S545-552.
16. Coeffier, M., Dechelotte, P., The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutr. Rev. 2005, 63, 65-69.
17. Dechelotte, P., Hasselmann, M., Cynober, L., Allaouchiche, B., L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit. Care Med. 2006, 34, 598-604.
18. Wischmeyer, P.E., Glutamine: role in critical illness and ongoing clinical trials. Curr. Opin. Gastroenterol. 2008, 24, 190-197.
19. Alpers, D.H., Glutamine: do the data support the cause for glutamine supplementation in humans? Gastroenterology 2006, 130, S106-116.
20. Semenza, G.L., Life with oxygen. Science 2007, 318, 62-64.
21. Fang, Y.Z., Yang, S., Wu, G., Free radicals, antioxidants, and nutrition. Nutrition 2002, 18, 872-879.
22. Pavlick, K.P., Laroux, F.S., Fuseler, J., Wolf, R.E. et al., Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic. Biol. Med. 2002, 33, 311-322.
23. Laviano, A., Meguid, M.M., Preziosa, I., Fanelli, F.R., Oxidative stress and wasting in cancer. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10, 449-456.
24. Reimund, J.M., Arondel, Y., Escalin, G., Finck, G. et al., Immune activation and nutritional status in adult Crohn's disease patients. Dig. Liver Dis. 2005, 37, 424-431.
25. Preiser, J.C., Van Gossum, A., Berre, J., Vincent, J.L., Carpentier, Y., Enteral feeding with a solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative stress. Crit. Care Med. 2000, 28, 3828-3832.
26. Beale, R.J., Sherry, T., Lei, K., Campbell-Stephen, L. et al., Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. Crit. Care Med. 2008, 36, 131-144.
27. Minami, H., Morse, E.L., Adibi, S.A., Characteristics and mechanism of glutamine-dipeptide absorption in human intestine. Gastroenterology 1992, 103, 3-11.
28. Kersey, P.J., Duarte, J., Williams, A., Karavidopoulou, Y. et al., The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004, 4, 1985-1988.
29. Dennis, G., Jr., Sherman, B.T., Hosack, D.A., Yang, J., et al., DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4, P3.
30. Nelson, J., McFerran, N.V., Pivato, G., Chambers, E. et al., The 67 kDa laminin receptor: structure, function and role in disease. Biosci. Rep. 2008, 28, 33-48.
31. Morel, E., Andrieu, T., Casagrande, F., Gauczynski, S. et al., Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am. J. Pathol. 2005, 167, 1033-1042.
32. Menard, S., Tagliabue, E., Colnaghi, M.I., The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res. Treat. 1998, 52, 137-145.
33. Kim, W.H., Lee, B.L., Jun, S.H., Song, S.Y., Kleinman, H.K., Expression of 32/67-kDa laminin receptor in laminin adhesion-selected human colon cancer cell lines. Br. J. Cancer 1998, 77, 15-20.
34. Givant-Horwitz, V., Davidson, B., Reich, R., Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res. 2004, 64, 3572-3579.
35. Satoh, K., Narumi, K., Abe, T., Sakai, T. et al., Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells. Br. J. Cancer 1999, 80, 1115-1122.
36. Umeda, D., Yano, S., Yamada, K., Tachibana, H., Green Tea Polyphenol Epigallocatechin-3-gallate Signaling Pathway through 67-kDa Laminin Receptor. J. Biol. Chem. 2008, 283, 3050-3058.
37. Pancholi, V., Multifunctional alpha-enolase: its role in diseases. Cell Mol. Life Sci. 2001, 58, 902-920.
38. Feo, S., Arcuri, D., Piddini, E., Passantino, R., Giallongo, A., ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoterbinding protein 1 (MBP-1). FEBS Lett. 2000, 473, 47-52.
39. Kim, J.W., Zeller, K.I., Wang, Y., Jegga, A.G. et al., Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell Biol. 2004, 24, 5923-5936.
40. Vermeulen, N., Arijs, I., Joossens, S., Vermeire, S. et al., Anti-alpha-enolase antibodies in patients with inflammatory bowel disease. Clin. Chem. 2008, 54, 534-541.
41. Sousa, L.P., Silva, B.M., Brasil, B.S., Nogueira, S.V., Plasminogen/plasmin regulates alpha-enolase expression through the MEK/ERK pathway. Biochem. Biophys. Res. Commun. 2005, 337, 1065-1071.
42. Perrier, J., Durand, A., Giardina, T., Puigserver, A., Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. Biochimie 2005, 87, 673-685.
43. Cigna, N., Nicoletti, C., Durand, A., Chaix, J.C. et al., Acylase 1 expression in rat intestinal crypt-villus axis. Cell Biol. Int. 2007, 31, 966-973.
44. Maceyka, M., Nava, V.E., Milstien, S., Spiegel, S., Aminoacylase 1 is a sphingosine kinase 1-interacting protein. FEBS Lett. 2004, 568, 30-34.
45. Hait, N.C., Oskeritzian, C.A., Paugh, S.W., Milstien, S., Spiegel, S., Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 2006, 1758, 2016-2026.
46. French, K.J., Schrecengost, R.S., Lee, B.D., Zhuang, Y. et al., Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63, 5962-5969.
47. Storch, J., Corsico, B., The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu. Rev. Nutr. 2008, 28, 73-95.
48. Pelsers, M.M., Namiot, Z., Kisielewski, W., Namiot, A. et al., Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 2003, 36, 529-535.
49. Wang, G., Gong, Y., Anderson, J., Sun, D. et al., Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 2005, 42, 871-879.
50. Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55, 1341-1349.
51. Wolfrum, C., Borrmann, C.M., Borchers, T., Spener, F., Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha-and gamma-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98, 2323-2328.
52. Poirier, H., Niot, I., Monnot, M.C., Braissant, O. et al., Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acidmediated inductions of the gene encoding liver fatty-acidbinding protein in the liver and the small intestine. Biochem. J. 2001, 355, 481-488.
53. Coeffier, M., Claeyssens, S., Lecleire, S., Leblond, J. et al., Combined enteral infusion of glutamine, carbohydrates, and antioxidants modulates gut protein metabolism in humans. Am. J. Clin. Nutr. 2008, 88, 1284-1290.
54. Lawrie, L.C., Dundas, S.R., Curran, S., Murray, G.I., Liver fatty acid binding protein expression in colorectal neoplasia. Br. J. Cancer 2004, 90, 1955-1960.
55. Das, R., Hammamieh, R., Neill, R., Melhem, M., Jett, M., Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin. Cancer Res. 2001, 7, 1706-1715.
56. Hammamieh, R., Chakraborty, N., Barmada, M., Das, R., Jett, M., Expression patterns of fatty acid binding proteins in breast cancer cells. J. Exp. Ther. Oncol. 2005, 5, 133-143.
57. Bhat, P.V., Retinal dehydrogenase gene expression in stomach and small intestine of rats during postnatal development and in vitamin A deficiency. FEBS Lett. 1998, 426, 260-262.
58. Ziouzenkova, O., Orasanu, G., Sharlach, M., Akiyama, T.E., Retinaldehyde represses adipogenesis and diet-induced obesity. Nat. Med. 2007, 13, 695-702.
59. Molotkov, A., Duester, G., Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. J. Biol. Chem. 2003, 278, 36085-36090.
60. Ziouzenkova, O., Plutzky, J., Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008, 582, 32-38.
61. Culotta, V.C., Yang, M., O'Halloran, T.V., Activation of superoxide dismutases: putting the metal to the pedal. Biochim. Biophys. Acta 2006, 1763, 747-758.
62. Aiken, K.J., Bickford, J.S., Kilberg, M.S., Nick, H.S., Metabolic regulation of manganese superoxide dismutase expression via essential amino acid deprivation. J. Biol. Chem. 2008, 283, 10252-10263.
63. Kruidenier, L., Kuiper, I., van Duijn, W., Marklund, S.L. et al., Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J. Pathol. 2003, 201, 7-16.
64. Behrend, L., Mohr, A., Dick, T., Zwacka, R.M., Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol. Cell. Biol. 2005, 25, 7758-7769.
65. Nelson, K.K., Ranganathan, A.C., Mansouri, J., Rodriguez, A.M. et al., Elevated sod2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin. Cancer Res. 2003, 9, 424-432.
66. Liu, Y., Borchert, G.L., Donald, S.P., Surazynski, A. et al., MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis 2005, 26, 1335-1342.